Select a Country Investors News Media Gallery Contact About Alexion Patient Focus Products Research and Development Careers Strensiq™ (asfotase alfa) Approved in EU for Treatment of Patients with Pediatric-Onset Hypophosphatasia (HPP). Learn More. Kanuma™ (sebelipase alfa) Approved in EU for Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D). Learn more. No is a word they’ve heard too often. Most patients with severe and life-threatening rare diseases live with no effective treatment options and no hope. We develop and deliver treatments that will dramatically transform their lives. Patient Stories We work relentlessly... Our entire global organization is focused on bringing breakthrough therapies to patients in need. Today, we are serving patients in 50 countries and advancing the most robust pipeline of innovative therapies in our history. Latest News view all news Featured Stories view all stories Alexion Joins aHUS Alliance in Recognizing International aHUS Awareness Day 2015 Read the Letter to Our Shareholders from Alexion's 2014 Annual Report David Hallal Becomes Chief Executive Officer of Alexion Alexion Opens New R&D Lab in Cambridge to Support mRNA Platform Making dramatic discoveries for patients with severe and life-threatening diseases. Our development pipeline is focused on highly innovative therapies with the potential to transform the lives of patients with devastating diseases who are often overlooked because of the rarity of their disorders. Research and Development Because if they ask whether there’s a treatment... Our global team is driven to provide patients with hope. Products We need to tell them yes. Every day we challenge ourselves to reach the ultimate goal of telling patients, “Yes,” there is a treatment. “Yes,” you will have access to it. And “Yes,” we’ll continue to serve patients by introducing new life-transforming treatments worldwide. Careers © 2015 Alexion Legal|Privacy Policy|Terms of Use|Site Map This website is intended only for residents of the United States.